Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ANGIOTENSIN II Cause Off label use? 17 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 17 reports of Off label use have been filed in association with ANGIOTENSIN II (Giapreza). This represents 9.4% of all adverse event reports for ANGIOTENSIN II.

17
Reports of Off label use with ANGIOTENSIN II
9.4%
of all ANGIOTENSIN II reports
10
Deaths
10
Hospitalizations

How Dangerous Is Off label use From ANGIOTENSIN II?

Of the 17 reports, 10 (58.8%) resulted in death, 10 (58.8%) required hospitalization, and 5 (29.4%) were considered life-threatening.

Is Off label use Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ANGIOTENSIN II. However, 17 reports have been filed with the FAERS database.

What Other Side Effects Does ANGIOTENSIN II Cause?

Drug ineffective (56) Death (20) Peripheral ischaemia (19) Acute kidney injury (15) Hypotension (13) Intestinal ischaemia (13) Toxicity to various agents (13) Deep vein thrombosis (11) Bradycardia (9) Distributive shock (9)

What Other Drugs Cause Off label use?

RITUXIMAB (39,751) INFLIXIMAB (34,801) DENOSUMAB (34,612) METHOTREXATE (24,020) VEDOLIZUMAB (21,017) ETANERCEPT (20,178) TOCILIZUMAB (18,256) PREDNISONE (17,867) LENALIDOMIDE (17,017) ADALIMUMAB (16,417)

Which ANGIOTENSIN II Alternatives Have Lower Off label use Risk?

ANGIOTENSIN II vs ANHYDROUS CITRIC ACID\ASPIRIN\SODIUM BICARBONATE ANGIOTENSIN II vs ANHYDROUS CITRIC ACID\MAGNESIUM\SODIUM PICOSULFATE ANGIOTENSIN II vs ANIDULAFUNGIN ANGIOTENSIN II vs ANIFROLUMAB ANGIOTENSIN II vs ANIFROLUMAB-FNIA

Related Pages

ANGIOTENSIN II Full Profile All Off label use Reports All Drugs Causing Off label use ANGIOTENSIN II Demographics